<table id="id_a26e7e5c-90e9-4bae-9c55-2bdcbcc56818" width="0.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_ba1758d0-f340-40f0-98a3-abebaaf09ac8">Table 3 Incidence of Primary Endpoint Events</caption>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<thead>
<tr id="id_e7ee007c-65c3-43a5-8f70-9afdc0a28003">
<td align="center" stylecode="Lrule Toprule" valign="top"> <br/>
</td>
<td align="center" colspan="2" stylecode="Toprule" valign="top"> Incidence</td>
<td align="center" stylecode="Toprule" valign="top"> Risk Reduction</td>
<td align="center" stylecode="Toprule" valign="top"> 95% C.I.</td>
<td align="center" stylecode="Rrule" valign="top"> p-Value</td>
</tr>
</thead>
<tbody>
<tr id="id_13971885-78d3-4352-8038-e8f9704f327a">
<td align="left" stylecode="Lrule Toprule" valign="top"> <br/>
</td>
<td align="center" stylecode="Toprule" valign="top"> Losartan</td>
<td align="center" stylecode="Toprule" valign="top"> Placebo</td>
<td align="center" stylecode="Toprule" valign="top"> </td>
<td align="center" stylecode="Toprule" valign="top"> <br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/>
</td>
</tr>
<tr id="id_b5a710f6-76fc-4961-830f-b788849b25d1">
<td align="left" stylecode="Lrule" valign="top"> <br/> Primary Composite<br/> Endpoint</td>
<td align="center" valign="top"> <br/>43.5%</td>
<td align="center" valign="top"> <br/>47.1%</td>
<td align="center" valign="top"> <br/>16.1%</td>
<td align="center" valign="top"> <br/>2.3% to 27.9%</td>
<td align="center" stylecode="Rrule" valign="top"> <br/>0.022</td>
</tr>
<tr id="id_bb6e5fb6-9e0b-40c3-bba7-b970e13b20b4">
<td align="left" colspan="6" stylecode="Lrule Rrule" valign="top">  Doubling of Serum Creatinine, ESRD and Death Occurring as a First Event</td>
</tr>
<tr id="id_d0936466-fdf1-4dee-8b3c-e00de3b35321">
<td align="left" stylecode="Lrule" valign="top"> Doubling of Serum<br/> Creatinine</td>
<td align="center" valign="top"> 21.6%</td>
<td align="center" valign="top">
<paragraph> 26.0%</paragraph>
</td>
<td align="center" valign="top"> <br/>
</td>
<td align="center" valign="top"> <br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/>
</td>
</tr>
<tr id="id_34f08a10-c155-4bfa-b90e-d8223f446ac1">
<td align="left" stylecode="Lrule" valign="top"> ESRD </td>
<td align="center" valign="top"> 8.5%</td>
<td align="center" valign="top"> 8.5%</td>
<td align="center" valign="top"> <br/>
</td>
<td align="center" valign="top"> <br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/>
</td>
</tr>
<tr id="id_74fc1560-d652-46e2-82b5-add93f1934d3">
<td align="left" stylecode="Lrule" valign="top"> Death</td>
<td align="center" valign="top"> 13.4%</td>
<td align="center" valign="top"> 12.6%</td>
<td align="center" valign="top"> <br/>
</td>
<td align="center" valign="top"> <br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/>
</td>
</tr>
<tr id="id_799b464b-eead-4ae2-aabf-8f5a0955b271">
<td align="left" colspan="6" stylecode="Lrule Rrule" valign="top">  Overall Incidence of Doubling of Serum Creatinine, ESRD and Death</td>
</tr>
<tr id="id_a57dfe0a-16f8-46f4-b8cf-d1324c1e50ef">
<td align="left" stylecode="Lrule" valign="top"> Doubling of Serum<br/> Creatinine</td>
<td align="center" valign="top"> 21.6%</td>
<td align="center" valign="top">26.0%</td>
<td align="center" valign="top"> 25.3%</td>
<td align="center" valign="top"> 7.8% to 39.4%</td>
<td align="center" stylecode="Rrule" valign="top"> 0.006</td>
</tr>
<tr id="id_b35bfb36-e378-4208-89dd-6a64a14586b1">
<td align="left" stylecode="Lrule" valign="top"> ESRD</td>
<td align="center" valign="top"> 19.6%</td>
<td align="center" valign="top"> 25.5%</td>
<td align="center" valign="top"> 28.6%</td>
<td align="center" valign="top"> 11.5% to 42.4%</td>
<td align="center" stylecode="Rrule" valign="top"> 0.002</td>
</tr>
<tr id="id_17e87cf0-0531-4a83-af31-2f14ded14035">
<td align="left" stylecode="Lrule Botrule" valign="top"> Death</td>
<td align="center" stylecode="Botrule" valign="top">21.0%</td>
<td align="center" stylecode="Botrule" valign="top"> 20.3%</td>
<td align="center" stylecode="Botrule" valign="top"> -1.7%</td>
<td align="center" stylecode="Botrule" valign="top"> -26.9% to 18.6%</td>
<td align="center" stylecode="Botrule Rrule" valign="top"> 0.884</td>
</tr>
</tbody>
</table>